the Synergistic Compatibility Framework
  • Home
  • What's Inside the Framework
  • SCF Developments
  • SCF Publications
  • SCF Systems Therapeutic’s AI Ecosystem

SCF VIRAGENESIS THERAPEUTIC BLUEPRINT

API DESIGN LAYER — SYSTEM ARCHITECTURE

I. FRAMEWORK OVERVIEW

Component
Description
Framework
SCF–PCR × Viragenesis × Multi-Omic Therapeutics
Objective
Reverse viral-genomic instability and restore host coherence
Target Domains
Genomic, Epigenetic, Bioenergetic, Immune
Output
Multi-API therapeutic system (stackable or modular)
Clinical Scope
Oncology, Autoimmune, Neurodegenerative, Fibrotic, Environmental Disease

II. VIRAGENESIS CASCADE → API TARGET MAP

Cascade Stage
Primary Disruption
Molecular Targets
API Design Goal
Stage 1: Genomic Instability
Viral integration / ERV activation
MLH1, MSH2, POLQ, ERV-LTRs
Restore repair fidelity, suppress integration
Stage 2: Epigenetic Drift
DNA methylation / histone alteration
DNMT1, HDACs, HATs
Rebalance chromatin state
Stage 3: Bioenergetic Collapse
NAD⁺ depletion, mitochondrial stress
SIRT1, PARP1, ETC complexes
Restore energy + redox balance
Stage 4: Immune Desynchronization
Chronic inflammation, immune tolerance loss
PD-1/PD-L1, NF-κB, IL-6
Normalize immune signaling

III. API SYSTEM CLUSTER DESIGN

Cluster A — Anti-Viragenic Genome Stabilizers

Parameter
Specification
API Code
VG-α1
Functional Class
DNA Repair Reactivator
Primary Targets
MLH1, MSH2, MSH6
Mechanism of Action
Enhances mismatch repair fidelity, reduces replication errors
Candidate Scaffolds
NAD⁺ boosters, PARP modulators, ATPase stabilizers
SCF Role
Restore genomic coherence
Delivery
Oral / IV / targeted nanoparticle

Cluster B — Epigenetic Reset Modulators

Parameter
Specification
API Code
VG-β2
Functional Class
Epigenetic Rebalancer
Targets
DNMT1, HDAC, histone acetylation pathways
Mechanism
Reverses CpG hypermethylation and
the Synergistic Compatibility Framework

About the Company

Contact

Regulatory Disclaimer

Terms of Use